Jenny McGovern, PhD

Quell Therapeutics
London, United Kingdom

Undergraduate at Manchester University, PhD in Rheumatology at University College London, 6 years post-doc and 6 years in Biotech at Quell Therapeutics

Presentation(s):

• 0006: QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis

  Sunday, October 26, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure(s): No financial relationships with ineligible companies to disclose